long intergenic non-protein coding RNA 1624Genealiases: []
Q-omics provides the consensus-scored LINC01624 profile across patient tissues and cancer cell-line models. LINC01624 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01624 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC01624 RNA expression shows 16,175 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where LINC01624 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01624 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01624 survival associations across molecular data types. LINC01624 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01624 RNA expression–survival associations across cancer types. High LINC01624 expression shows unfavorable associations in UVM and KIRP, but favorable associations in KIRC, HNSC, SKCM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01624 RNA expression.
This table summarizes LINC01624 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01624. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01624 shows lower tumor expression in COAD, LUAD, LUSC, BRCA and BLCA and higher tumor expression in KIRC. The COAD box plot shows higher LINC01624 RNA expression in normal versus tumor tissue (log2 FC = −0.208, t-test p < 0.001).
This table shows molecular features associated with LINC01624 in patient tissues and cancer cell lines. In patient samples, LINC01624 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
